IL24 and ovarian carcinoma: Accumulating evidence from experimental and clinical datasets consistently demonstrates decreased IL‐24 levels in lung (Ramesh et al. 2004), colorectal (Zhang et al. 2019), pancreatic (Jia et al. 2016), endometrial (Liao et al. 2020), head and neck (Qiu et al. 2020), ovarian cancers (Gopalan et al. 2007), melanoma (Ekmekcioglu et al. 2001), and glioblastoma (Lin et al. 2021), with no discernible impact on normal cells.